OBJECTIVES: Serum hepatitis B virus (HBV)-DNA > 2,000 IU/mL is associated with higher risk of disease progression. However, without hepatocellular carcinoma (HCC) or cirrhosis, nucleos(t)ide analogs (NUCs) are recommended only for patients with elevated serum HBV-DNA and alanine aminotransferase ≥2 × upper normal limit. METHODS: We evaluated prognosis of untreated minimally active (MA) hepatitis patients (defined as HBV-DNA > 2,000 IU/mL, but never fulfilling current criteria for NUCs during follow-up) (untreated MA group), compared to virological responders by NUCs (NUC-VR group). Eligible patients undergoing transient elastography were consecutively enrolled. Patients with an immune-tolerant or inactive phase and with cirrhosis or HCC at...
Background: Anti-viral therapy is not indicated for patients with chronic hepatitis B (CHB) in the i...
Background/Aims: Decay of hepatitis B surface antigen (HBsAg) titers has previously been shown to be...
read with interest the article by Degertekin and Lok on the indications for therapy in hepatitis B.1...
Nucleos(t)ide analogs (NUCs) are recommended when both are fulfilled in the absence of hepatocellula...
Routine nucleos(t)ide analogs (NUCs) have not yet been recommended for patients with immune-tolerant...
BACKGROUND & AIMS: We compared the risk of hepatocellular carcinoma (HCC) development between patien...
Introduction: The necessity of antiviral therapy (AVT) for hepatitis B virus (HBV)-infected compensa...
BACKGROUND & AIMS: The risk and the predictors of liver disease progression in carriers of inactive ...
Xinhui Wang, Xiaoli Liu, Peng Wang, Lihua Yu, Fengna Yan, Huiwen Yan, Dongdong Zhou, Zhiyun Yang Cen...
Background and aims: Hepatocellular carcinoma (HCC) risk in chronic hepatitis B (CHB) substantially ...
Nucleos(t)ide analogues (NAs), which are widely used as the first-line anti-hepatitis B virus (HBV) ...
BACKGROUND: Long-term oral nucleos(t)ide analogue (NUC) therapy in hepatitis B virus (HBV)-related ...
ObjectiveTo investigate the effect of sustained virologic response on disease progression and the de...
PURPOSE: The effectiveness of nucleoside analogue on patients with chronic hepatitis B-associated li...
Objectives We investigated whether long-term clinical outcomes such as disease progression or inac-t...
Background: Anti-viral therapy is not indicated for patients with chronic hepatitis B (CHB) in the i...
Background/Aims: Decay of hepatitis B surface antigen (HBsAg) titers has previously been shown to be...
read with interest the article by Degertekin and Lok on the indications for therapy in hepatitis B.1...
Nucleos(t)ide analogs (NUCs) are recommended when both are fulfilled in the absence of hepatocellula...
Routine nucleos(t)ide analogs (NUCs) have not yet been recommended for patients with immune-tolerant...
BACKGROUND & AIMS: We compared the risk of hepatocellular carcinoma (HCC) development between patien...
Introduction: The necessity of antiviral therapy (AVT) for hepatitis B virus (HBV)-infected compensa...
BACKGROUND & AIMS: The risk and the predictors of liver disease progression in carriers of inactive ...
Xinhui Wang, Xiaoli Liu, Peng Wang, Lihua Yu, Fengna Yan, Huiwen Yan, Dongdong Zhou, Zhiyun Yang Cen...
Background and aims: Hepatocellular carcinoma (HCC) risk in chronic hepatitis B (CHB) substantially ...
Nucleos(t)ide analogues (NAs), which are widely used as the first-line anti-hepatitis B virus (HBV) ...
BACKGROUND: Long-term oral nucleos(t)ide analogue (NUC) therapy in hepatitis B virus (HBV)-related ...
ObjectiveTo investigate the effect of sustained virologic response on disease progression and the de...
PURPOSE: The effectiveness of nucleoside analogue on patients with chronic hepatitis B-associated li...
Objectives We investigated whether long-term clinical outcomes such as disease progression or inac-t...
Background: Anti-viral therapy is not indicated for patients with chronic hepatitis B (CHB) in the i...
Background/Aims: Decay of hepatitis B surface antigen (HBsAg) titers has previously been shown to be...
read with interest the article by Degertekin and Lok on the indications for therapy in hepatitis B.1...